
News|Articles|November 15, 2012
Testimony: FDA Commissioner says FDA has limited authority over compounding pharmacies to prevent meningitis outbreak
FDA Commissioner Margaret Hamburg was asked if the fungal meningitis outbreak could have been prevented by FDA during a 4-hour hearing Nov. 14 headed by the chairman of the House Energy and Commerce oversight subcommittee. Her answer was that FDA had limited authority because the New England Compounding Center (NECC), Framingham, Mass., was a ?compounding pharmacy,? which is regulated by the state Board of Pharmacy.
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Early trial of linvoseltamab shows promise for newly diagnosed multiple myeloma patients | ASH 2025
2
Gene therapy in the real world: High priced, a long process and still relatively few patients | ASH 2025
3
Findings suggest linvoseltamab could be a useful new option for new multiple myeloma patients | ASH 2025
4
Jaypirca shows promise as a frontline treatment for CLL/SLL patients | ASH 2025
5





















































